Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies

Sanjiv S. Gambhir; Lalitha K. Shankar; Eben Rosenthal; Jason M. Warram; Munir Ghesani; Thomas A. Hope; Paula M. Jacobs; Gunilla B. Jacobson; Terri Wilson; Barry A. Siegel

doi:10.2967/jnumed.118.219824

Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies

Sanjiv S. Gambhir, Lalitha K. Shankar, Eben Rosenthal, Jason M. Warram, Munir Ghesani, Thomas A. Hope, Paula M. Jacobs, Gunilla B. Jacobson, Terri Wilson, Barry A. Siegel

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	736-744
Number of pages	9
Journal	Journal of Nuclear Medicine
Volume	60
Issue number	6
DOIs	https://doi.org/10.2967/jnumed.118.219824
State	Published - Jun 2019

Access to Document

10.2967/jnumed.118.219824

Cite this

@article{1ee290b151af4f9f8f1405a93225f43e,

title = "Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies",

author = "Gambhir, {Sanjiv S.} and Shankar, {Lalitha K.} and Eben Rosenthal and Warram, {Jason M.} and Munir Ghesani and Hope, {Thomas A.} and Jacobs, {Paula M.} and Jacobson, {Gunilla B.} and Terri Wilson and Siegel, {Barry A.}",

note = "Funding Information: Thomas Hope is on the JNM editorial board. Barry A. Siegel is a JNM consulting editor; an advisory board member for Blue Earth Diagnostics and GE Healthcare; and a consultant for Avid Radiopharmaceuticals, Inc., BTG Management Services, Capella Imaging, LLC, Curium Pharma, ImaginAb, Inc., Merrimack Pharmaceuticals, Inc., and Progenics Pharmaceuticals, Inc. He also receives clinical trial support from Blue Earth Diagnostics and Progenics Pharmaceuticals, Inc. Sanjiv S. Gambhir has active imaging grants from Sanofi-Aventis, US, Inc., Biogen Inc., Novocure, Philips Medical, and Pliant Therapeutics, Inc. He is a cofounder of CellSight Technologies, Endra Life Sciences, and Earli Inc. He is on the advisory boards of Centella Therapeutics, Inc., Click Diagnostics, Verily, ImaginAb, MagArray Inc., Konica-Minolta Inc., Vave Inc., Nines Inc., NinePoint Medical, GE Healthcare (ad hoc), Alpha Source Inc., RefleXion Medical, Spectrum Dynamics, Vor Biopharma, TauMark Inc., Piramal MI, Life Molecular Imaging, Infinitus Inc., NuvOx Inc., Bracco Inc., Grail Inc., and VisualSonics/Fuji Inc. No other potential conflict of interest relevant to this article was reported.",

year = "2019",

month = jun,

doi = "10.2967/jnumed.118.219824",

language = "English",

volume = "60",

pages = "736--744",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

number = "6",

}

TY - JOUR

T1 - Proceedings

T2 - Pathways for successful translation of new imaging agents and modalities—phase III studies

AU - Gambhir, Sanjiv S.

AU - Shankar, Lalitha K.

AU - Rosenthal, Eben

AU - Warram, Jason M.

AU - Ghesani, Munir

AU - Hope, Thomas A.

AU - Jacobs, Paula M.

AU - Jacobson, Gunilla B.

AU - Wilson, Terri

AU - Siegel, Barry A.

N1 - Funding Information: Thomas Hope is on the JNM editorial board. Barry A. Siegel is a JNM consulting editor; an advisory board member for Blue Earth Diagnostics and GE Healthcare; and a consultant for Avid Radiopharmaceuticals, Inc., BTG Management Services, Capella Imaging, LLC, Curium Pharma, ImaginAb, Inc., Merrimack Pharmaceuticals, Inc., and Progenics Pharmaceuticals, Inc. He also receives clinical trial support from Blue Earth Diagnostics and Progenics Pharmaceuticals, Inc. Sanjiv S. Gambhir has active imaging grants from Sanofi-Aventis, US, Inc., Biogen Inc., Novocure, Philips Medical, and Pliant Therapeutics, Inc. He is a cofounder of CellSight Technologies, Endra Life Sciences, and Earli Inc. He is on the advisory boards of Centella Therapeutics, Inc., Click Diagnostics, Verily, ImaginAb, MagArray Inc., Konica-Minolta Inc., Vave Inc., Nines Inc., NinePoint Medical, GE Healthcare (ad hoc), Alpha Source Inc., RefleXion Medical, Spectrum Dynamics, Vor Biopharma, TauMark Inc., Piramal MI, Life Molecular Imaging, Infinitus Inc., NuvOx Inc., Bracco Inc., Grail Inc., and VisualSonics/Fuji Inc. No other potential conflict of interest relevant to this article was reported.

PY - 2019/6

Y1 - 2019/6

UR - http://www.scopus.com/inward/record.url?scp=85067000560&partnerID=8YFLogxK

U2 - 10.2967/jnumed.118.219824

DO - 10.2967/jnumed.118.219824

M3 - Article

C2 - 30850482

AN - SCOPUS:85067000560

SN - 0161-5505

VL - 60

SP - 736

EP - 744

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 6

ER -

Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies

Access to Document

Other files and links

Cite this